Evidence map›Paper›PMID 42515028›Full record

ArticlePathogens (Basel, Switzerland)2026

Patient-Reported Health-Related Quality of Life Impact and Symptom Severity in Patients with Lyme Borreliosis in the Burden of Lyme Disease (BOLD) Study.

Holly Yu, Amanda R Mercadante, Kate Halsby, Alexandra Loew-Baselli, Ye Tan, Juanita Edwards, Frederick J Angulo, Elizabeth Begier, Mendwas Dzingina, Johan S Berglund and 4 more

Abstract read
In one paragraph

Article in Pathogens (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Holly YuPfizer Inc., HTA Value and Evidence, Collegeville, PA 19426, USA.ORCID 0000-0001-8625-4201
Amanda R MercadantePfizer Inc., HTA Value and Evidence, New York, NY 10001, USA.ORCID 0000-0002-4576-4405
Kate HalsbyPfizer Research & Development, Tadworth, Surrey KT20 7NS, UK.
Alexandra Loew-BaselliPfizer Research & Development/Pfizer Corporation Austria GmbH, 1210 Vienna, Austria.ORCID 0000-0003-2924-0836
Ye TanPfizer Inc., Evidence Generation Statistics, Cambridge, MA 02139, USA.
Juanita EdwardsPfizer Inc., HTA Value and Evidence, Collegeville, PA 19426, USA.
Frederick J AnguloPfizer Inc., HTA Value and Evidence, Collegeville, PA 19426, USA.
Elizabeth BegierPfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, D04 K7N3 Dublin, Ireland.
Mendwas DzinginaPfizer Research & Development, Tadworth, Surrey KT20 7NS, UK.
Johan S BerglundDepartment of Health, Blekinge Institute of Technology, Valhallavägen 1, 371 79 Karlskrona, Sweden.ORCID 0000-0003-4312-2246
Anna Moniuszko-MalinowskaDepartment of Infectious Diseases and Neuroinfections, Medical University of Białystok, ul. Zurawia 14, blok D, 15-540 Białystok, Poland.ORCID 0000-0002-3994-8785
Franc StrleDepartment of Infectious Diseases, University Medical Centre Ljubljana, Japljeva 2, 1525 Ljubljana, Slovenia.ORCID 0000-0003-4163-0503
James H StarkPfizer Inc., Evidence Generation Statistics, Cambridge, MA 02139, USA.
On Behalf Of The Bold Study Group

Funding

Pfizer (USA) N/AValneva (Austria) N/A
6 · The paper itself

Abstract

Lyme borreliosis (LB) can manifest as a localized infection or, if left untreated, disseminated disease. This analysis used Patient-Reported Outcome tools to assess general health, fatigue, pain, and cognitive function in patients with localized or disseminated LB, compared with age- and site-matched controls without LB. All participants were enrolled in the Burden of Lyme Disease (BOLD) study; LB cases were assessed at 3 time points: the enrollment visit, and two follow-up visits conducted within 10 months of enrollment. Controls were evaluated at 2 time points: the enrollment contact and a follow-up contact 16-18 months post-enrollment. Symptom severity and general health quality between groups were compared using two-tailed Student's

Indexed as

Lyme DiseaseQuality of LifeAdultAgedFatigueFemaleHumansMaleMiddle AgedPainPatient Reported Outcome MeasuresSeverity of Illness IndexSymptom Burdendisseminated LBlocalized LBLyme borreliosisLyme diseasepatient-reported outcomesquality of life

Identifiers

PMID42515028
PMCPMC13414593

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.